Ocular Hypertension

Cardiovascular
19
Pipeline Programs
7
Companies
14
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
2
0
7
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 14 programs with unclassified modality

On Market (4)

Approved therapies currently available

U
TAFLUPROSTApproved
tafluprost
Unknown Company
Prostaglandin Analog [EPC]ophthalmic2024
U
TIMOLOLApproved
timolol
Unknown Company
ophthalmic2016
Bausch + Lomb
VYZULTAApproved
latanoprostene bunod
Bausch + Lomb
ophthalmic2017
Thea Pharma
ZOLYMBUSApproved
bimatoprost
Thea Pharma
Prostaglandin Analog [EPC]ophthalmic2025

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
3 programs
1
1
1
Brinzolamide 1%/brimonidine 0.2% ophthalmic suspensionPhase 41 trial
Netarsudil 0.01%/latanoprost 0.005% ophthalmic solutionPhase 31 trial
MGV354 ophthalmic suspensionPhase 1/2
Active Trials
NCT07082816Active Not Recruiting489Est. May 2026
NCT01937299Completed307Est. Apr 2014
Bausch + Lomb
Bausch + LombNJ - Bridgewater
2 programs
1
1
Latanoprostene BunodPhase 41 trial
BOL-303259-XPhase 21 trial
Active Trials
NCT01707381Completed25Est. Feb 2014
NCT04140279Withdrawn0Est. Aug 2023
Pfizer
PfizerNEW YORK, NY
2 programs
1
1
latanoprost 0.005%Phase 41 trial
timololPhase 3Small Molecule1 trial
Active Trials
NCT00751049Completed294Est. Dec 1993
NCT00140062Completed329Est. Apr 2006
Thea Pharma
Thea PharmaMA - Waltham
1 program
1
1
BimatoprostPhase 31 trial
Active Trials
NCT03825380CompletedEst. Feb 2021
S
SantenCA - Emeryville
4 programs
4
Timolol and TafluprostPhase 31 trial
Timolol/ FDC/ Placebo/ TafluprostPhase 31 trial
tafluprostPhase 31 trial
tafluprostPhase 31 trial
Active Trials
NCT01306461Completed401Est. May 2012
NCT01292460Completed600Est. Sep 2012
NCT01087671Completed185Est. Oct 2010
+1 more trials
Sylentis
SylentisSpain - Madrid
2 programs
1
1
SYL040012Phase 21 trial
SYL040012Phase 11 trial
Active Trials
NCT00990743CompletedEst. Jun 2010
NCT01739244CompletedEst. May 2013
Novartis
NovartisBASEL, Switzerland
1 program
1
SAD448Phase 11 trial
Active Trials
NCT00503360Completed80

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch + LombLatanoprostene Bunod
AlconBrinzolamide 1%/brimonidine 0.2% ophthalmic suspension
Pfizerlatanoprost 0.005%
AlconNetarsudil 0.01%/latanoprost 0.005% ophthalmic solution
Thea PharmaBimatoprost
SantenTimolol and Tafluprost
SantenTimolol/ FDC/ Placebo/ Tafluprost
Santentafluprost
Santentafluprost
Pfizertimolol
Bausch + LombBOL-303259-X
SylentisSYL040012
SylentisSYL040012
NovartisSAD448

Clinical Trials (14)

Total enrollment: 2,860 patients across 14 trials

NCT04140279Bausch + LombLatanoprostene Bunod

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

Start: May 2022Est. completion: Aug 20230
Phase 4Withdrawn
NCT01937299AlconBrinzolamide 1%/brimonidine 0.2% ophthalmic suspension

Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®

Start: Oct 2013Est. completion: Apr 2014307 patients
Phase 4Completed
NCT00140062Pfizerlatanoprost 0.005%

Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.

Start: Feb 2002Est. completion: Apr 2006329 patients
Phase 4Completed
NCT07082816AlconNetarsudil 0.01%/latanoprost 0.005% ophthalmic solution

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

Start: Sep 2025Est. completion: May 2026489 patients
Phase 3Active Not Recruiting
NCT03825380Thea PharmaBimatoprost

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Start: Nov 2018Est. completion: Feb 2021
Phase 3Completed
NCT01306461SantenTimolol and Tafluprost

Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

Start: Mar 2011Est. completion: May 2012401 patients
Phase 3Completed
NCT01292460SantenTimolol/ FDC/ Placebo/ Tafluprost

Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies

Start: Feb 2011Est. completion: Sep 2012600 patients
Phase 3Completed
NCT01087671Santentafluprost

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops

Start: Apr 2010Est. completion: Oct 2010185 patients
Phase 3Completed
NCT00596791Santentafluprost

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

Start: Jan 2008Est. completion: Aug 2008150 patients
Phase 3Completed
NCT00751049Pfizertimolol

A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom

Start: Dec 1992Est. completion: Dec 1993294 patients
Phase 3Completed
NCT01707381Bausch + LombBOL-303259-X

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Start: Nov 2012Est. completion: Feb 201425 patients
Phase 2Completed
NCT01739244SylentisSYL040012

Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma

Start: Jul 2012Est. completion: May 2013
Phase 2Completed
NCT00990743SylentisSYL040012

Tolerance and Effect on Intraocular Pressure After Administration of SYL040012

Start: Sep 2009Est. completion: Jun 2010
Phase 1Completed
NCT00503360NovartisSAD448

Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension

Start: Apr 200780 patients
Phase 1Completed

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
19h ago
From $150K/yr

Clinical Consultant

Johnson & Johnson
North Ryde, New South Wales, Australia
20h ago

Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
20h ago
$100K - $135K/yr

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
20h ago

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
20h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)